Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Stéphane HuaUniversité Paris-Saclay, Inserm, CEA; Immunological diseases, microbiology and innovative therapies (IDMIT/UMRS1184), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
Keltouma BenmezianeUniversité Paris-Saclay, Inserm, CEA; Immunological diseases, microbiology and innovative therapies (IDMIT/UMRS1184), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
Delphine DesjardinsUniversité Paris-Saclay, Inserm, CEA; Immunological diseases, microbiology and innovative therapies (IDMIT/UMRS1184), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.ORCID http://orcid.org/0000-0002-5820-3914
Nastasia DimantUniversité Paris-Saclay, Inserm, CEA; Immunological diseases, microbiology and innovative therapies (IDMIT/UMRS1184), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.ORCID http://orcid.org/0009-0004-3252-4789
Marco LeonecUniversité Paris-Saclay, Inserm, CEA; Immunological diseases, microbiology and innovative therapies (IDMIT/UMRS1184), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
Laetitia BossevotUniversité Paris-Saclay, Inserm, CEA; Immunological diseases, microbiology and innovative therapies (IDMIT/UMRS1184), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.ORCID http://orcid.org/0000-0002-5752-9277
Julien LemaitreUniversité Paris-Saclay, Inserm, CEA; Immunological diseases, microbiology and innovative therapies (IDMIT/UMRS1184), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.ORCID http://orcid.org/0000-0001-6239-0110
Roger Le GrandUniversité Paris-Saclay, Inserm, CEA; Immunological diseases, microbiology and innovative therapies (IDMIT/UMRS1184), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.ORCID http://orcid.org/0000-0002-4928-4484
Mariangela CavarelliUniversité Paris-Saclay, Inserm, CEA; Immunological diseases, microbiology and innovative therapies (IDMIT/UMRS1184), Fontenay-aux-Roses & Le Kremlin-Bicêtre, France. mariangela.cavarelli@cea.fr.ORCID http://orcid.org/0000-0002-8468-0263
Funding
Sidaction na
6 · The paper itself
Abstract
Achieving durable viral remission without antiretroviral therapy (ART) remains a central challenge in HIV-1 cure research. Using a pathogenic SIV model in male cynomolgus macaques, we investigated mucosal and systemic immune features associated with post-treatment control (PTC). Chronic SIV infection disrupts intestinal macrophage homeostasis, skewing the compartment toward a CX3CR1
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Maintenance of intestinal CX3CR1 · full record | OpenQuestion